ArticleEFSA journal. European Food Safety Authority2021
Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 1:
Article in EFSA journal. European Food Safety Authority, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Occurrence and Antimicrobial Resistance Profiles ofBiology · 2026Article
- Safety evaluation of the food enzyme subtilisin from the genetically modifiedEFSA journal. European Food Safety Authority · 2026Article
- Guidance on the characterisation of microorganisms in support of the risk assessment of products used in the food chain.EFSA journal. European Food Safety Authority · 2025Article
- Ecology-based approach to predict no-effect antibiotic concentrations for minimizing environmental selection of resistance.The ISME journal · 2025Article
- Selection for florfenicol resistance at sub-MIC concentrations in Pasteurella multocida.PloS one · 2025Article
- Safety evaluation of the food enzyme subtilisin from the non-genetically modifiedEFSA journal. European Food Safety Authority · 2024Article
- Rapid testing of antibiotic residues to increase food safety awareness of animal origin.Veterinary world · 2024Article
- Article
- Safety evaluation of the food enzyme subtilisin from the non-genetically modifiedEFSA journal. European Food Safety Authority · 2023Article
- Antibiotic Minimal Selective Concentrations and Fitness Costs during Biofilm and Planktonic Growth.mBio · 2022Article
- Qualitative Risk Assessment for Antimicrobial Resistance among Humans from Salmon Fillet Consumption Due to the High Use of Antibiotics against Bacterial Infections in Farmed Salmon.Antibiotics (Basel, Switzerland) · 2022Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 13:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 12:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 7:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 9:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 6:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 5:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 4:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 2:EFSA journal. European Food Safety Authority · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 1:EFSA journal. European Food Safety Authority · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Commission requested EFSA to assess, in collaboration with EMA, the specific concentrations of antimicrobials resulting from cross-contamination in non-target feed for food-producing animals below which there would not be an effect on the emergence of, and/or selection for, resistance in microbial agents relevant for human and animal health, as well as the levels of the antimicrobials which could have a growth promotion/increase yield effect. The assessment was performed for 24 antimicrobial active substances, as specified in the mandate. This scientific opinion describes the methodology used, and the main associated data gaps and uncertainties. To estimate the antimicrobial levels in the non-target feed that would not result in emergence of, and/or selection for, resistance, a model was developed. This 'Feed Antimicrobial Resistance Selection Concentration' (FARSC) model is based on the minimal selective concentration (MSC), or the predicted MSC (PMSC) if MSC for the most susceptible bacterial species is unavailable, the fraction of antimicrobial dose available for exposure to microorganisms in the large intestine or rumen (considering pharmacokinetic parameters), the daily faecal output or rumen volume and the daily feed intake. Currently, lack of data prevents the establishment of PMSC and/or FARSC for several antimicrobials and animal species. To address growth promotion, data from an extensive literature search were used. Specific assessments of the different substances grouped by antimicrobial classes are addressed in separate scientific opinions. General conclusions and recommendations were made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.